Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Wynn Resorts, Limited (WYNN) Price & Performance

Charles River Laboratories Intl. IncTrade
Wynn Resorts, LimitedTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Wynn Resorts, Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Wynn Resorts, Limited trades at $103.25 (market cap $10.79B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLWYNN
Market Cap
$13.46B$10.79B
Sector
HealthConsumer Cyclical
52-Week High
$282.00$133.34
52-Week Low
$145.57$94.37
Enterprise Value
$16.30B$21.03B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Wynn Resorts, Limited

Wynn Resorts (WYNN) trades at $103.51, up 0.99% today, showing steady recovery from pandemic lows. The stock maintains bullish technical signals with strong institutional support, though faces headwinds from high debt levels and margin pressure. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.99 estimate, driven by Macau strength, while Las Vegas operations show slower growth. Analyst consensus remains strongly bullish with 64% buy ratings and $133 price target, representing 28% upside potential.

Investment outlook balances growth potential against significant risks. The company's Macau recovery and UAE expansion provide growth catalysts, but high leverage ($10.5B debt) and rising capex for Wynn Al Marjan project create cash flow pressure. Current valuation at 25x P/E appears reasonable given recovery trajectory, but investors should monitor margin trends and capital expenditure discipline closely given the negative shareholder equity position.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Wynn Resorts, Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.

Read more on WYNN